UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  FORM 10-K  (Mark One)  X. ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Fiscal Year Ended: May 31, 2014 OR  . TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________  Commission file number: 000-52782  RAMBO MEDICAL GROUP, INC.(Exact name of registrant as specified in its charter)  Nevada26-2113613(State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)  800 E. Colorado Blvd., Suite 888Pasadena, CA 91101(Address of principal executive offices) (Zip Code)  Registrants telephone number: (626) 683-7330  Securities registered under Section 12(b) of the Act: None  Securities registered under Section 12(g) of the Act: Common Stock, par value $0.00001 par value  Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes . No X.  Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes . No X..  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X. No .  Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X. No .  Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. . .   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a smaller reporting company.See the definitions of the large accelerated filer, accelerate filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.(Check one):  Large accelerated filer.Accelerated filer.Non-accelerated filer. (Do not check if a smaller reporting company)Smaller reporting companyX.  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes X. No .  As of September 15, 2014, there were 991,192 shares of the registrants common stock, par value $0.00001, issued and outstanding.   2   TABLE OF CONTENTS


|                           |                                                                                                              |      |   
|-------------------------- | ------------------------------------------------------------------------------------------------------------ | ---- | --
|Item Number and Caption    |                                                                                                              | Page
|                           |                                                                                                              |      |   
|FORWARD-LOOKING STATEMENTS |                                                                                                              | 4   
|                           |                                                                                                              |      |   
|PART I                     |                                                                                                              |      |   
|                           |                                                                                                              |      |   
|ITEM 1.                    | BUSINESS                                                                                                     |      | 5 
|ITEM 1A.                   | RISK FACTORS                                                                                                 |      | 8 
|ITEM 1B.                   | UNRESOLVED STAFF COMMENTS                                                                                    |      | 12
|ITEM 2.                    | PROPERTIES                                                                                                   |      | 12
|ITEM 3.                    | LEGAL PROCEEDINGS                                                                                            |      | 13
|ITEM 4.                    | MINE SAFETY DISCLOSURES                                                                                      |      | 13
|                           |                                                                                                              |      |   
|PART II                    |                                                                                                              |      |   
|                           |                                                                                                              |      |   
|ITEM 5.                    | MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES |      | 13
|ITEM 6.                    | SELECTED FINANCIAL DATA                                                                                      |      | 14
|ITEM 7.                    | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS                        |      | 14
|ITEM 7A                    | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                                                   |      | 17
|ITEM 8.                    | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA                                                                  |      | 17
|ITEM 9.                    | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE                         |      | 17
|ITEM 9A.                   | CONTROLS AND PROCEDURES                                                                                      |      | 18
|ITEM 9B.                   | OTHER INFORMATION                                                                                            |      | 19
|                           |                                                                                                              |      |   
|PART III                   |                                                                                                              |      |   
|                           |                                                                                                              |      |   
|ITEM 10.                   | DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE                                                      |      | 19
|ITEM 11.                   | EXECUTIVE COMPENSATION                                                                                       |      | 21
|ITEM 12.                   | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS               |      | 22
|ITEM 13.                   | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE                                    |      | 23
|ITEM 14.                   | PRINCIPAL ACCOUNTING FEES AND SERVICES                                                                       |      | 23
|                           |                                                                                                              |      |   
|PART IV                    |                                                                                                              |      |   
|                           |                                                                                                              |      |   
|ITEM 15.                   | EXHIBITS, FINANCIAL STATEMENT SCHEDULES                                                                      |      | 24

3    FORWARD-LOOKING STATEMENTS  Except for historical information, this Annual Report on Form 10-K (this Annual Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Such forward-looking statements include, among others, those statements including the words believes, anticipates, expects, intend, estimate, plan and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions and the following:  · our status as a development stage company; · our selection of a prospective target business or asset; · our issuance of our capital shares or incurrence of debt to complete a business combination; · removal of our securities from OTC Markets quotation system, or the ability to have our securities quoted on OTC Markets or listed on a national exchange following our business combination; · our ability to consummate an attractive business combination due to our limited resources and the significant competition for business combination opportunities; · conflicts of interest of our officers and directors; · potential current or future affiliations of our officers and directors with competing businesses; · our ability to obtain additional financing if necessary; · the control by our existing stockholders of a substantial interest in us; · our being deemed an investment company; · our dependence on our key personnel; · our dependence on a single company after our business combination; · business and market outlook; · our and our customers business strategies following the consummation of a business combination; · environmental, obtaining permits and other regulatory risks following the consummation of a business combination; · foreign currency fluctuations and overall political risk in foreign jurisdictions following the consummation of a business combination; · operating and capital expenditures by us following the consummation of a business combination; · our competitive position following the consummation of a business combination; · outcomes of legal proceedings following the consummation of a business combination; · expected results of operations and/or financial position following the consummation of a business combination; · future effective tax rates; and · compliance with applicable laws.  These risks and others described below under Item 1A. Risk Factors are not exhaustive.  Given these uncertainties, readers of this Annual Report and investors are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.  All references in this Annual Report to the Company, Rambo, we, us or our are to Rambo Medical Group, Inc.             4    PART I       ITEM 1. BUSINESS  Business Development  We were incorporated in the State of Nevada on November 18, 2005, under the name Cobra Oil and Gas Company. We were formed to engage in identifying, investigating, exploring, and where determined advantageous, developing, mining, refining, and marketing oil and gas.  On October 14, 2009, we filed an amendment to our Articles of Incorporation to change our name to Viper Resources, Inc., and increase our authorized capitalization from 200,000,000 shares, consisting of 100,000,000 shares of common stock, $0.00001 par value and 100,000,000 shares of preferred stock, $0.00001 par value to 400,000,000 shares, consisting of 300,000,000 shares of common stock $0.00001 par value and 100,000,000 shares of preferred stock, $0.00001 par value.  Since inception, we were in the exploration stage as an oil and gas exploration company. During the fiscal year ended May 31, 2014, we engaged in no oil and gas activities, had minimal operations, and generated no revenues. In May 2012, our management determined to discontinue our oil and gas operations, and attempt to acquire other assets or business operations that will maximize shareholder value.  On August 5, 2013 we filed a Certificate of Amendment to effect a 1:100 reverse stock split of our common stock and change our name to Rambo Medical Group, Inc. The Certificate of Amendment became effective on August 9, 2013. All share amounts referred in this Annual Report give effect to the reverse split including those applicable to periods prior to the reverse split. We are currently in negotiations to acquire or combine with a company which operates in the medical diagnostics industry and chose our new name in furtherance thereof. No definitive agreement has been reached and no assurance can be given that we will successfully complete and close the proposed acquisition or business combination. Should we fail to do so, we may seek alternative acquisitions with companies engaged in the medical diagnostics industry or unrelated industries.  Our Proposed Business Activities  We intend to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for our shareholders. Our objectives discussed below are extremely general and are not intended to restrict our discretion. This discussion of the proposed business is not meant to be restrictive of our virtually unlimited discretion to search for and enter into potential business opportunities.  Except as discussed above under Business Development, we have no particular acquisition in mind and have not entered into any negotiations regarding such an acquisition and neither our officers nor any affiliate has engaged in any negotiations with any representative of any company regarding the possibility of an acquisition or merger between our company and such other company. We have not yet entered into any agreement, nor do we have any commitment or understanding to enter into or become engaged in a transaction.  We will not restrict our potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. Further, we may acquire a venture which is in its preliminary or development stage, one which is already in operation, or in a more mature stage of its corporate existence. Accordingly, business opportunities may be available in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities difficult and complex.   5    We believe that there are numerous firms seeking the perceived benefits of a publicly registered corporation. These benefits are commonly thought to include the following:  · the ability to use registered securities to acquire assets or businesses; · increased visibility in the marketplace; · ease of borrowing from financial institutions; · improved stock trading efficiency; · shareholder liquidity; · greater ease in subsequently raising capital; · compensation of key employees through stock options; · enhanced corporate image; and · a presence in the United States capital market.  We have not conducted market research and are not aware of statistical data to support the perceived benefits of a merger or acquisition transaction for the owners of a business opportunity.  Target companies interested in a business combination with us may include the following:  · a company for whom a primary purpose of becoming public is the use of its securities for the acquisition of other assets or businesses; · a company which is unable to find an underwriter of its securities or is unable to find an underwriter of securities on terms acceptable to it; · a company which desires to become public with less dilution of its common stock than would occur upon an underwriting; · a company which believes that it will be able to obtain investment capital on more favorable terms after it has become public; · a foreign company which may wish an initial entry into the United States securities market; · a special situation company, such as a company seeking a public market to satisfy redemption requirements under a qualified employee stock option plan; · a company seeking one or more of the other mentioned perceived benefits of becoming a public company.  We anticipate seeking out a target business through solicitation. Such solicitation may include newspaper or magazine advertisements, mailings and other distributions to law firms, accounting firms, investment bankers, financial advisors and similar persons, the use of one or more websites and similar methods. No estimate can be made as to the number of persons who will be contacted or solicited.  The analysis of new business opportunities will be undertaken by or under the supervision of our executive officers and directors, none of whom is a business analyst. Therefore, it is anticipated that outside consultants or advisors may be utilized to assist us in the search for and analysis of qualified target companies.  A decision to participate in a specific business opportunity will be made based upon our analysis of the quality of the prospective business opportunitys management and personnel, assets, the anticipated acceptability of products or marketing concepts, the merit of a proposed business plan, and numerous other factors which are difficult, if not impossible, to analyze using any objective criteria. We have unrestricted flexibility in seeking, analyzing and participating in potential business opportunities.  In our efforts to analyze potential acquisition targets, we will consider the following kinds of factors:  · potential for growth, indicated by new technology, anticipated market expansion or new products; · competitive position as compared to other firms of similar size and experience within the industry segment as well as within the industry as a whole; · strength and diversity of management, either in place or scheduled for recruitment; · capital requirements and anticipated availability of required funds, to be provided by our company or from operations, through the sale of additional securities, through joint ventures or similar arrangements or from other sources; · the cost of participation by our company as compared to the perceived tangible and intangible values and potentials; · the extent to which the business opportunity can be advanced; · the accessibility of required management expertise, personnel, raw materials, services, professional assistance and other required items; and · other relevant factors.  6    In applying the foregoing criteria, no one of which will be controlling, management will attempt to analyze all factors and circumstances and make a determination based upon reasonable investigative measures and available data.  Potentially available business opportunities may occur in many different industries, and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex. Due to our limited capital available for investigation, we may not discover or adequately evaluate adverse facts about the opportunity to be acquired.  In implementing a structure for a particular business acquisition, we may become a party to a merger, consolidation, reorganization, joint venture, or licensing agreement with another entity. We also may acquire stock or assets of an existing business. On the consummation of a transaction it is probable that the present management and shareholders of the company will no longer be in control of the company. In addition, our officers and directors, as part of the terms of the acquisition transaction, likely will be required to resign and be replaced by one or more new officers and directors without a vote of our shareholders.  It is anticipated that any securities issued in any such reorganization would be issued in reliance upon exemption from registration under applicable federal and state securities laws. In some circumstances, however, as a negotiated element of a transaction, we may agree to register all or a part of such securities immediately after the transaction is consummated or at specified times thereafter. The issuance of substantial additional securities and their potential sale into any trading market which may develop in our securities may have a depressive effect on that market.  While the actual terms of a transaction to which we may be a party cannot be predicted, it may be expected that the parties to the business transaction will find it desirable to avoid the creation of a taxable event and thereby structure the acquisition as a tax-free reorganization under Sections 351 or 368 of the Internal Revenue Code of 1986, as amended.  With respect to any merger or acquisition, negotiations with target company management are expected to focus on the percentage of our company which the target company shareholders would acquire in exchange for all of their shareholdings in the target company. Depending upon, among other things, the target companys assets and liabilities, our shareholders will in all likelihood hold a substantially lesser percentage ownership interest in our company following any merger or acquisition. The percentage ownership may be subject to significant reduction in the event we acquire a target company with substantial assets. Any merger or acquisition effected by us can be expected to have a significant dilutive effect on the percentage of shares held by our shareholders at such time.  We will participate in a business opportunity only after the negotiation and execution of appropriate agreements. Although the terms of such agreements cannot be predicted, generally such agreements will require certain representations and warranties of the parties thereto, will specify certain events of default, will detail the terms of closing and the conditions which must be satisfied by the parties prior to and after such closing, will outline the manner of bearing costs, including costs associated with our attorneys and accountants, and will include miscellaneous other terms.  We are presently subject to all of the reporting requirements included in the Exchange Act. Included in these requirements is our duty to file audited financial statements as part of our Form 8-K to be filed with the Securities and Exchange Commission (SEC) upon consummation of a merger or acquisition, as well as our audited financial statements included in its annual report on Form 10-K. If such audited financial statements are not available at closing, or within time parameters necessary to insure our compliance with the requirements of the Exchange Act, or if the audited financial statements provided do not conform to the representations made by the target company, the closing documents may provide that the proposed transaction will be voidable at the discretion of our present management.  It is anticipated that the investigation of specific business opportunities and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require substantial management time and attention and substantial cost for accountants, attorneys and others. If a decision is made not to participate in a specific business opportunity, the costs theretofore incurred in the related investigation would not be recoverable. Furthermore, even if an agreement is reached for the participation in a specific business opportunity, the failure to consummate that transaction may result in our loss of the related costs incurred.  Under SEC Rule 12b-2 under the Securities Act, we are deemed to be a shell company, because we have nominal assets (other than cash) and nominal operations. Management does not intend to undertake any efforts to cause a market to develop in our securities, either debt or equity, until we have successfully concluded a business combination. We intend to comply with the periodic reporting requirements of the Exchange Act for so long as we are subject to those requirements.  7    Competition  We expect to encounter substantial competition in our efforts to acquire a business opportunity. The primary competition is from other companies organized and funded for similar purposes, small venture capital partnerships and corporations, small business investment companies and wealthy individuals. In view of our limited financial resources and limited management availability, we may be at a competitive disadvantage compared to our competitors.  Employees  We presently have no employees apart from our management. Each of our officers is engaged in outside business activities and anticipates that he will devote to our business very limited time until the acquisition of a successful business opportunity has been identified. We expect no significant changes in the number of our employees other than such changes, if any, incident to a business combination.  We intend to hire additional management and other support personnel when we have reached a point in our proposed growth that would allow for such employment. In the interim, we will rely upon consultants to assist us in identifying and investigating acquisition opportunities.  Reports to Security Holders  We file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports, statement or other information that we file with the SEC at the SECs public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at (202) 551-8090 for further information on the public reference room. These SEC filings are also available to the public from commercial document retrieval services and at the Internet site maintained by the SEC at http://www.sec.gov.  In addition our filings can be viewed on our Internet site at www.viper-resources.com.  ITEM 1A. RISK FACTORS  An investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors before deciding to invest in our company. If any of the following risks actually occur, our business, financial condition, results of operations and prospects for growth would likely suffer. As a result, you may lose all or part of your investment in our company.  We are a development stage company and may never be able to effectuate our business plan.  Since inception, we were in the exploration stage as an oil and gas exploration company. In May 2012, our management determined to discontinue our oil and gas operations, and attempt to acquire other assets or business operations that will maximize shareholder value. We intend to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for our shareholders. As a development stage company we may not be able to successfully effectuate our business plan. There can be no assurance that we will ever achieve any revenues or profitability. The revenue and income potential of our proposed business and operations is unproven as the lack of operating history makes it difficult to evaluate the future prospects of our business.  We require financing to acquire businesses and implement our business plan. We cannot assure you that we will be successful in obtaining financing or acquiring businesses, or in operating those acquired businesses in a profitable manner.  We expect losses in the future because we have no revenue.  As we have no current revenue, we are expecting losses over the next 12 months because we do not yet have any revenues to offset the expenses associated with our business plan. We cannot guarantee that we will ever be successful in generating revenues in the future. We recognize that if we are unable to generate revenues, we will not be able to earn profits or continue operations. There is no history upon which to base any assumption as to the likelihood that we will prove successful, and we can provide investors with no assurance that we will generate any operating revenues or ever achieve profitable operations.  8    If our business plans are not successful, we may not be able to continue operations as a going concern and our stockholders may lose their entire investment in us.  Since inception, we have had no revenues and incurred a cumulative net loss of $7,147,156 through May 31, 2014. This raises substantial doubt about our ability to continue as a going concern. We will, in all likelihood, sustain operating expenses without corresponding revenues, at least until the consummation of a business combination. This may result in our incurring a net operating loss that will increase continuously until we can consummate a business combination with a profitable business opportunity. We cannot assure you that we can identify a suitable business opportunity and consummate a business combination. If we cannot continue as a going concern, our stockholders may lose their entire investment in us.  We do not have any definitive agreements for a business combination or other transaction.  Although we are currently in negotiations to acquire or combine with a company which operates in the medical diagnostics industry, we have no present arrangement, agreement or understanding with respect to engaging in a merger with, joint venture with or acquisition of, such company or any other private or public entity. We cannot assure you that we will successfully identify and evaluate suitable business opportunities or that we will conclude a business combination. Management has not identified any particular industry or specific business within an industry for evaluation. We cannot guarantee that we will be able to negotiate a business combination on favorable terms, and there is consequently a risk that future funds allocated to the purchase of our shares will not be invested in a company with active business operations.  Future success is highly dependent on the ability of management to locate and attract a suitable acquisition.  The success of our proposed plan of operation will depend to a great extent on the operations, financial condition and management of any identified target company. While business combinations with entities having established operating histories are preferred, there can be no assurance that we will be successful in locating candidates meeting such criteria. The decision to enter into a business combination will likely be made without detailed feasibility studies, independent analysis, market surveys or similar information which, if we had more funds available to it, would be desirable. In the event we complete a business combination the success of our operations will be dependent upon management of the target company and numerous other factors beyond our control. We cannot assure you that we will identify a target company and consummate a business combination.  There is competition for those private companies suitable for a merger transaction of the type contemplated by management.  We are in a highly competitive market for a small number of business opportunities which could reduce the likelihood of consummating a successful business combination. We are and will continue to be an insignificant participant in the business of seeking mergers with, joint ventures with and acquisitions of small private and public entities. A large number of established and well-financed entities, including small public companies and venture capital firms, are active in mergers and acquisitions of companies that may be desirable target candidates for us. Nearly all these entities have significantly greater financial resources, technical expertise and managerial capabilities than we do; consequently, we will be at a competitive disadvantage in identifying possible business opportunities and successfully completing a business combination. These competitive factors may reduce the likelihood of our identifying and consummating a successful business combination.  Management intends to devote only a limited amount of time to seeking a target company which may adversely impact our ability to identify a suitable acquisition candidate.  While seeking a business combination, management anticipates devoting very limited time to our affairs in total. None of our officers has entered into a written employment agreement with us and is not expected to do so in the foreseeable future. This limited commitment may adversely impact our ability to identify and consummate a successful business combination.  We are dependent on the services of our executive officers to obtain capital required to implement our business plan and for identifying, investigating, negotiating and integrating potential acquisition opportunities. The loss of services of senior management could have a substantial adverse effect on us. The expansion of our business will be largely contingent on our ability to attract and retain highly qualified corporate and operations level management team. We cannot assure you that we will find suitable management personnel or will have financial resources to attract or retain such people if found.  9    The time and cost of preparing a private company to become a public reporting company may preclude us from entering into a merger or acquisition with the most attractive private companies.  Target companies that fail to comply with SEC reporting requirements may delay or preclude acquisition. Sections 13 and 15(d) of the Exchange Act require reporting companies to provide certain information about significant acquisitions, including audited financial statements for the company acquired.  The time and additional costs that may be incurred by some target entities to prepare these statements may significantly delay or essentially preclude consummation of an acquisition. Otherwise suitable acquisition prospects that do not have or are unable to obtain the required audited statements may be inappropriate for acquisition so long as the reporting requirements of the Exchange Act are applicable.  We may be subject to further government regulation which would adversely affect our operations.  Although we are subject to the reporting requirements under the Exchange Act, management believes we will not be subject to regulation under the Investment Company Act of 1940, as amended (the Investment Company Act), since we will not be engaged in the business of investing or trading in securities. If we engage in business combinations which result in our holding passive investment interests in a number of entities, we could be subject to regulation under the Investment Company Act. If so, we would be required to register as an investment company and could be expected to incur significant registration and compliance costs. We have obtained no formal determination from the SEC as to our status under the Investment Company Act and, consequently, violation of the Investment Company Act could subject us to material adverse consequences.  Any potential acquisition or merger with a foreign company may subject us to additional risks.  If we enter into a business combination with a foreign concern, we will be subject to risks inherent in business operations outside of the United States. These risks include, for example, currency fluctuations, regulatory problems, punitive tariffs, unstable local tax policies, trade embargoes, risks related to shipment of raw materials and finished goods across national borders and cultural and language differences. Foreign economies may differ favorably or unfavorably from the United States economy in growth of gross national product, rate of inflation, market development, rate of savings, and capital investment, resource self-sufficiency and balance of payments positions, and in other respects.  We may need to raise additional capital to expand our operations and execute our business plan. If our operations do not produce the necessary cash flow, or if we cannot obtain needed funds, we may be forced to reduce or cease our activities with consequent loss to investors.  We have a need for cash in order to pay obligations currently due in a timely manner, and to finance our business operations. Our continued operations will depend upon the sustainability of cash flow from our ability to raise additional funds, as required, through equity or debt financing. There is no assurance that we will be able to obtain additional funding when it is needed, or that such funding, if available, will be obtainable on terms acceptable to us. If we cannot obtain needed funds, we may be forced to reduce or cease our activities with consequent loss to investors. In addition, should we incur significant presently unforeseen expenses or delays, we may not be able to accomplish our goals.   10    If we fail to develop and maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud, as a result, current and potential shareholders could lose confidence in our financial reports, which could harm our business and the trading price of our common stock.  Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate and report on our internal controls over financial reporting and have our independent registered public accounting firm annually attest to our evaluation. We plan to prepare for compliance with Section 404 by strengthening, assessing and testing our system of internal controls to provide the basis for our report. The process of strengthening our internal controls and complying with Section 404 is expensive and time consuming, and requires significant management attention, especially given that we have not yet undertaken any efforts to comply with the requirements of Section 404. We cannot be certain that the measures we will undertake will ensure that we will maintain adequate controls over our financial processes and reporting in the future. Furthermore, if we are able to rapidly grow our business, the internal controls that we will need will become more complex, and significantly more resources will be required to ensure our internal controls remain effective. Failure to implement required controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. If we or our auditors discover a material weakness in our internal controls, the disclosure of that fact, even if the weakness is quickly remedied, could diminish investors confidence in our financial statements and harm our stock price. In addition, non-compliance with Section 404 could subject us to a variety of administrative sanctions, including the suspension of trading, ineligibility for listing on the OTC Bulletin Board, one of the national securities exchanges, and the inability of registered broker-dealers to make a market in our common stock, which would further reduce our stock price.  Our principal stockholders, officers and director owns a controlling interest in our voting stock and investors will not have any voice in our management, which could result in decisions adverse to our general shareholders.  Our officers beneficially own in the aggregate approximately 50.5% of our outstanding common stock. As a result, our management will have the ability to control substantially all matters submitted to our stockholders for approval including: (a) election of our Board of Directors (Board); (b) removal of any of our directors; (c) amendments of our Certificate of Incorporation or bylaws; (d) adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us, or (e) other significant corporate transactions.  Our failure to adopt certain corporate governance procedures may prevent us from obtaining a listing on a national securities exchange.  We have only one director, and he is not independent as that term is defined in the rules of any national securities exchange. As a result, we do not have an Audit or Compensation Committee. The functions of those committees are conducted by the Board. Consequently, there is a potential conflict of interest in Board decisions that may adversely affect our ability to become a listed security on a national securities exchange and as a result adversely affect the liquidity of our common stock.  Trading in our shares of common stock is limited, and will not improve unless we increase our sales, become profitable and secure more active market makers.  There is a limited trading market for our common stock. There can be no assurance that a regular trading market for our securities will continue to develop or that it will be sustained. The trading price of our securities could be subject to wide fluctuations, in response to quarterly variations in our operating results, announcements by us or others, developments affecting us, and other events or factors. In addition, the stock market has experienced extreme price and volume fluctuations in recent years. These fluctuations have had a substantial effect on the market prices for many companies, often unrelated to the operating performance of such companies, and may adversely affect the market prices of the securities Such risks could have an adverse effect on the stocks future liquidity.  We may, in the future, issue additional common shares, which would reduce investors percent of ownership and may dilute our share value.  Our Certificate of Incorporation, as amended, authorizes the issuance of 400,000,000 shares, consisting of 300,000,000 shares of common stock, $0.00001 par value per share, and 100,000,000 shares of preferred stock, $0.00001 par value per share. The future issuance of stock, including shares that may be issued upon conversion of shares of preferred stock, may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors, and might have an adverse effect on any trading market for our common stock.  11    Our Board of Directors is authorized to issue up to 100 million shares of preferred stock with powers, rights and preferences designated by it which may be issued to create voting impediments or to frustrate persons seeking to effect a takeover or otherwise gain control of our company, thereby preventing you from realizing a premium over the market value of your shares.  Our Board is authorized to issue up to 100 million shares of preferred stock with powers, rights and preferences designated by it. Shares of voting or convertible preferred stock could be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate persons seeking to effect a takeover or otherwise gain control of our company. The ability of the Board to issue such additional shares of preferred stock, with rights and preferences it deems advisable, could discourage an attempt by a party to acquire control of our company by tender offer or other means. Such issuances could therefore deprive stockholders of benefits that could result from such an attempt, such as the realization of a premium over the market price for their shares in a tender offer or the temporary increase in market price that such an attempt could cause. Moreover, the issuance of such additional shares of preferred stock to persons friendly to the Board could make it more difficult to remove incumbent managers and directors from office even if such change were to be favorable to stockholders generally.  Our common shares are subject to the Penny Stock Rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.  The SEC has adopted Rule 15g-9 which establishes the definition of a penny stock, for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a persons account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.  In order to approve a persons account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person; and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.  The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the penny stock rules. This may make it more difficult for investors to dispose of our Common shares and cause a decline in the market value of our stock.  Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.  Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.  We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. We cannot assure you that you will be able to sell shares when you desire to do so.  ITEM 1B. UNRESOLVED STAFF COMMENTS  Not Applicable.  ITEM 2. PROPERTIES  Our executive offices are located at 800 East Colorado Boulevard, Suite 888, Pasadena, CA 91101 and cover an area of approximately 8,142 square feet. The use of these offices is supplied to us on a rent free basis by an affiliated party.  12    ITEM 3. LEGAL PROCEEDINGS  From time to time we may be a defendant and plaintiff in various legal proceedings arising in the normal course of our business. We are currently not a party to any material legal proceedings or government actions, including any bankruptcy, receivership, or similar proceedings. In addition, we are not aware of any threatened litigation or action that could affect our operations. Furthermore, as of the date of this Annual Report, our management is not aware of any proceedings to which any of our directors, officers, or affiliates, or any associate of any such director, officer, affiliate, or security holder is a party adverse to our company or has a material interest adverse to us.  ITEM 4. MINE SAFETY DISCLOSURES  Not Applicable. PART II  ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES  Market Information  Our common stock was quoted on the OTC Bulletin Board of the National Association of Securities Dealers, Inc. (the NASD) under the symbol CGCA.OB from July 20, 2007 until November 6, 2009, from November 6, 2009 until August 9, 2013 under the symbol VPRS.OB, and since August 9, 2013 under the symbol RMGI.PK. The following table sets forth, for the fiscal quarters indicated, the high and low closing bid prices per share of our common stock, as derived from quotations provided by Pink Sheets, LLC. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.  Quarter EndedHigh Bid(1)Low Bid(1)May 31, 2014$.20$.10February 28, 2014$.52$.19November 30, 2013$1.00$.02August 31, 2013$1.50$.01May 31, 2013$1.50$1.05February 28, 2013$1.40$.50November 30, 2012$1.60$1.25August 31, 2012$2.15$1.10  (1) Prices before August 9, 2013 give retroactive effect to the 1:100 reverse stock split which was effected on August 9, 2013.  Holders  As of September 15, 2014 there were approximately 11 record holders of our common stock.  Dividends  We have never declared any cash dividends with respect to our common stock. Future payment of dividends is within the discretion of our Board of Directors and will depend on our earnings, capital requirements, financial condition and other relevant factors. Although there are no material restrictions limiting, or that are likely to limit, our ability to pay dividends on our common stock, we presently intend to retain future earnings, if any, for use in our business and have no present intention to pay cash dividends on our common stock.  Recent Sales of Unregistered Securities  We sold no unregistered securities during the year ended May 31, 2014.  13    Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies  Historically, the SEC staff has taken the position that Rule 144 is not available for the resale of securities initially issued by companies that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical compliance with the requirements of Rule 144. The SEC has codified and expanded this position in recent amendments by prohibiting the use of Rule 144 for resale of securities issued by any shell companies (other than business combination related shell companies) or any issuer that has been at any time previously a shell company. The SEC has provided an exception to this prohibition, however, if the following conditions are met:  · the issuer of the securities that was formerly a shell company has ceased to be a shell company; · the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; · the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and · at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.  As a result, our existing stockholders will not be able to sell the shares pursuant to Rule 144 without registration one year after we have completed our initial business combination assuming we meet the four conditions of a former shell company stated above at such time.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers  None  Securities Authorized For Issuance Under Equity Compensation Plans  We do not presently maintain any equity compensation plans and have not maintained any such plans since our inception.       ITEM 6. SELECTED FINANCIAL DATA  Not applicable.  ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  The following discussion should be read in conjunction with our audited consolidated financial statements and the accompanying notes included elsewhere in this 

Annual Report.

 The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors, including those discussed elsewhere in this 

Annual Report

..  Historically, we were in the exploration stage as an oil and gas exploration company. During the fiscal year ended May 31, 2014, we engaged in no oil and gas activities, had minimal operations, and generated no revenues. In May 2012, our management determined to discontinue our oil and gas operations, and attempt to acquire other assets or business operations that will maximize shareholder value. We are currently in negotiations to acquire or combine with a company which operates in the medical diagnostics industry. No assurance can be given that we will successfully reach an agreement with such company and successfully complete and close the proposed acquisition or business combination. No other specific assets or businesses have been definitively identified and there is no certainty that any such assets or business will be identified or any transactions will be consummated.  Our plan is to seek a business venture in which to participate. The selection of a business opportunity in which to participate is complex and extremely risky and will be made by management in the exercise of its business judgment. There is no assurance that we will be able to identify and acquire any business opportunity that will ultimately prove to be beneficial to us and our shareholders.  14    We are pursuing our search for a business opportunity primarily through our officers and directors, although other sources, such as professional advisors, securities broker-dealers, venture capitalists, members of the financial community, and others, may present unsolicited proposals. Our activities are subject to several significant risks that arise primarily as a result of the fact that we have no specific business and may acquire or participate in a business opportunity based on the decision of management which will, in all probability, act without the consent, vote, or approval of our shareholders. A description of the manner in which we will pursue the search for and participation in a business venture is described above.  We expect that we will need to raise funds in order to effectuate our business plans. We intend initially to seek additional investors to purchase our stock to provide us with working capital to fund our operations. Thereafter, we will seek to establish or acquire businesses or assets with additional funds raised either via the issuance of shares or debt. There can be no assurance that additional capital will be available to us. We may seek to raise the required capital by other means. We may have to issue debt or equity or enter into a strategic arrangement with a third party. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds will have a severe negative impact on our ability to remain a viable company. In pursuing the foregoing goals, we may seek to expand or change the composition of the Board or make changes to our current capital structure, including issuing additional shares or debt and adopting a stock option plan.  We do not expect to generate any revenues over the next twelve months. Our principal business objective for the next 12 months will be to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for our shareholders.  During the next 12 months we anticipate incurring costs related to filing of Exchange Act reports, and costs relating to consummating an acquisition. We believe we will be able to meet these costs through use of funds in our treasury and additional amounts, as necessary, to be loaned by or invested in us by our stockholders, management or other investors. We have no specific plans, understandings or agreements with respect to the raising of such funds, and we may seek to raise the required capital by the issuance of equity or debt securities or by other means. Since we have no such arrangements or plans currently in effect, our inability to raise funds for the consummation of an acquisition may have a severe negative impact on our ability to become a viable company. We estimate that the level of working capital needed for these general and administrative costs for the next twelve months will be approximately $150,000. However, this estimate is subject to change, depending on the number of transactions in which we ultimately become involved. In addition, funding will be required for follow-on development of working interest obligations of any successful exploration prospects.  In its report dated September 15, 2014, our auditors, Anton & Chia, LLP expressed an opinion that there is substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. We have generated no operating revenues since our inception. We had an accumulated deficit of $7,147,156 as of May 31, 2014. Our continuation as a going concern is dependent upon future events, including our ability to raise additional capital and to generate positive cash flows.  Presently we have no employees except for our four executive officers consisting of Dianwen Ju, Jimmy Wang, Xiao Chen and Guofeng Xu. Changes in the number of employees during the next twelve months will be a function of the level of business activity.  We intend to contract out certain technical and administrative functions on an as-needed basis in order to conduct our operating activities. Our management team will select and hire these contractors and manage and evaluate their work performance.  Results of Operations  Revenues  We have had no revenues since our inception.  Expenses  We had operating expenses of $41,610 and $38,090 for the years ended May 31, 2014 and 2013 respectively. The increase in operating expenses during the year ended May 31, 2014 was attributable to an increase in general and administrative expenses.  15    Net Loss  We incurred net losses for the years ended May 31, 2014 and 2013 of $41,610 and $38,090, respectively. The increase in net loss was directly attributable to a increase in general and administrative expenses.  Liquidity and Capital Resources  At May 31, 2014 we had a working capital deficit of $102,943 compared to a working capital deficit of $61,333 at May 31, 2013. Current liabilities increased to $109,650 at May 31, 2014 from $65,791 at May 31, 2013 due to decrease in accounts payable and an increase in loans payable. Current assets increased from $4,458 at May 31, 2013 to $6,707 at May 31, 2014 due to an increase in cash and cash equivalents.  We will attempt to raise capital for our current operational needs through loans from related parties, debt financing, equity financing or a combination of financing options. However, there are no existing understandings, commitments or agreements for extension of outstanding notes or an infusion of capital, and there are no assurances to that effect. Moreover, our need for capital may change dramatically if and during that period, we acquire an interest in a business opportunity. There can be no assurances that any additional financings will be available to us on satisfactory terms and conditions, if at all. Unless we can obtain additional financing, our ability to continue as a going concern is doubtful.  Critical Accounting Policies and Estimates  Cash and Cash Equivalents  We consider all highly liquid investments with an original maturity of three months or less as cash equivalents.  Use of Estimates  The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  Income Tax  We account for income taxes under Accounting Standard Codification 740 (ASC 740). Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.  Net Income (Loss) per share  The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of our preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.  Revenue Recognition  Revenue is recognized on an accrual basis as earned under contract terms. We have had no revenue to date.  16    Financial Instruments  The carrying value of our financial instruments, including cash and cash equivalents, as reported in our balance sheet, approximates fair value.  Stock Based Compensation  We account for employee and non-employee stock awards under ASC 718, whereby equity instruments issued to employees for services are recorded based on the fair value of the instrument issued and those issued to non-employees are recorded based on the fair value of the consideration received or the fair value of the equity instrument, whichever is more reliably measurable.  Recent Accounting Pronouncements  Refer to Note 3 to the Financial Statements included in Item 8 of this Annual Report, which discusses new accounting pronouncements we adopted, as well as accounting pronouncements recently issued or proposed but not yet required to be adopted.  Off Balance Sheet Arrangements  None.  Contractual Obligations  Not applicable.   ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK  Not applicable   ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA  See the Financial Statements and notes thereto commencing on page F-1.       ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE  On February 13, 2014, KLJ & Associates, LLP (KLJ) resigned as certifying independent accountant and contemporaneous with the resignation of KLJ, the Registrant engaged Anton & Chia, LLP (AC) as the Companys independent registered public accountant.  17    The report of KLJ & Associates on the financial statements of the Company for the fiscal year ended May 31, 2013 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that such report included an explanatory paragraph with respect to the Companys ability, in light of its lack of revenues and history of losses, to continue as a going concern.  During the fiscal years ended May 31, 2013 and the subsequent interim periods through February 13, 2014, there were no: (i) disagreements with KLJ on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedure which, if not resolved to the satisfaction of KLJ, would have caused KLJ to make reference to the matter in their report, or (ii) reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.       Prior to February 13, 2014, the Company did not consult with AC regarding (1) the application of accounting principles to a specific transaction, (2) the type of audit opinion that might be rendered on the Companys financial statements, (3) written or oral advice provided that would be an important factor considered by the Company in reaching a decision as to an accounting, auditing or financial reporting issue, or (4) any matter that was the subject of a disagreement between the Company and its predecessor auditor as described in Item 304(a)(1)(iv) or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.  ITEM 9A. CONTROLS AND PROCEDURES  Evaluation of Our Disclosure Controls and Internal Controls  We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SECs rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended May 31, 2014 we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13(a)-15(e) and 15d-15(e) under the 1934 Act. Based on this evaluation, management concluded that, as of May 31, 2014, our disclosure controls and procedures were effective.  Managements Report on Internal Control over Financial Reporting  Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.  Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; (ii) provide reasonable assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Management assessed the effectiveness of our internal control over financial reporting as of May 31, 2014 based on the framework established in Internal ControlIntegrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that assessment, management concluded that, as of May 31, 2014, our internal control over financial reporting was effective based on the criteria established in Internal ControlIntegrated Framework.  18    Limitations on Effectiveness of Controls and Procedures  Our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Our control systems are designed to provide such reasonable assurance of achieving their objectives. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.  Changes in Internal Controls  During the fiscal year ended May 31, 2014, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.       ITEM 9B. OTHER INFORMATION  Not applicable.        PART III       ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE  Executive Officers, Directors and Key Employees  Directors serve until the next annual meeting of the stockholders, until their successors are elected or appointed and qualified, or until their prior resignation or removal. Officers serve for such terms as determined by our Board. Each officer holds office until such officers successor is elected or appointed and qualified or until such officers earlier resignation or removal. No family relationships exist between any of our present directors and officers.  The following table sets forth certain information, as of May 31, 2014, with respect to our directors and executive officers.  NamePositions HeldAgeDate of Election or Appointment as DirectorDianwen JuPresident and Chief Executive Officer, Sole Director45April 25, 2011Jimmy WangTreasurer47N/AXiao ChenChief Financial Officer41N/AGuofeng XuSecretary34N/A  The following is a brief account of the business experience during the past five years or more of each of our directors and executive officers.  19    Dianwen Ju, Ph.D. has served as our President, Chief Executive Officer and sole Director since April 25, 2011. He received a Ph.D. degree in Immunology in 1999, a Masters degree in Pharmacology in 1994, and a Bachelors degree in Pharmacy in 1991 in Second Military Medical University, Shanghai, China. He joined Shanghai MediPharm Biotech in 2002 as a director of R&D and he is currently CEO and Chairman of MediPharm Biotech Pharmaceuticals Co. Ltd (Bermuda). He is also a Research Professor in Fudan University, Shanghai, China. He has 20 years of R&D experiences in biological drugs and new therapies for the treatment of malignant cancer. He has more than 40 publications in peer-reviewed international journals including Journal of Clinical Oncology, Cancer Research, Gene Therapy, International Journal of Oncology, Cancer Gene Therapy, Cancer Immunology & Immunotherapy, et al. He has invented 15 biotechnologies of which 8 are patented and the remaining 7 are pending. Before joining MediPharm in 2002, Dr. Ju had been an assistant director and a senior scientist in Shanghai Brilliance Biotech Institute and a lecturer in Immunology in Second Military Medical University for 6 years. Mr. Ju brings to our Board a wealth of experience derived from his services in various businesses. He has demonstrated strong acumen and ability to exercise sound judgment and has a reputation for integrity, honesty and adherence to ethical standards.  Jimmy Wang has served as our Treasurer since April 25, 2011. He is the Chief Financial Officer of American Compass, Inc., where he has served, initially as Chief Accounting Officer, since 2003. Prior to joining American Compass, Inc., he served as an accounting manager for Planned Parenthood of the Greater Miami Valley from 2000 to 2003. He has served as a Director for Nevada Gold Holdings, Inc. since January 25, 2011. He is a graduate of the City University of New York, where he majored in both Accounting & Information Systems and Economics.  Xiao Chen has served as our Chief Financial Officer since April 25, 2011. He worked at Brilliance China Group from 1994 to 2001. From 2005 to 2008, he worked as director of finance at Shanghai Medipharm Co. Ltd. Since 2008, Mr. Chen has been working at Hybrid Kinetic Group Limited as vice general manager of investments in China. Mr. Chen holds a bachelors degree in investment management from Shanghai Finance University.  Guofeng Xu has served as our Secretary since November 21, 2011. He performed Ph.D. Research involving the identification of new metalloprotease genes at the University of Virginia in Charlottesville, Virginia from August 2004 until December 2011. From August 2001 until June 2004 he performed M.S. Research in Shanghai, China involving the anti-cancer drug Onconase. Mr. Xu received a Ph.D. in Cell Biology from the University of Virginia in 2011 and a B.D. in Biological Science and Technologies from Zhejiang University in Hangzhou China in 2001.  Board of Directors; Board Committees  Our directors do not receive any remuneration for acting as such. Our directors may however be reimbursed their expenses, if any, for attendance at meetings of the Board. Our Board may designate from among its members an executive committee and one or more other committees. No such committees presently exist, due to the fact that we presently have only one director. Accordingly, we do not have an audit committee or an audit committee financial expert. We are presently not required to have an audit committee financial expert and do not believe we otherwise need one at this time due to our limited business operations. Similarly we do not have a nominating committee or a committee performing similar functions. Our sole director, Dianwen Ju, serves the functions of an audit committee and a nominating committee. We have not implemented procedures by which our security holders may recommend board nominees to us but expect to do so in the future, when and if we engage in material business operations.  Corporate Governance  Leadership Structure  Our Board has one member, Dianwen Ju. Accordingly, we have not designated a chairman.  We are a small, development stage company which has yet to achieve operating revenues. We believe that our present management structure is appropriate for a company of our size and state of development.  Our Board is actively involved in our risk oversight function and collectively undertakes our risk oversight function. This review of our risk tolerances includes, but is not limited to, financial, legal and operational risks and other risks concerning our reputation and ethical standards.  Given our size, we do not have a nominating committee or a diversity policy. Our Board monitors and assesses the need for and qualifications of additional directors. We may adopt a diversity policy in the future in connection with our anticipated growth.  20    Compliance with Section 16(a) of the Exchange Act  Section 16(a) of the Exchange Act, as amended, requires that our directors, executive officers and persons who own more than 10% of a class of our equity securities that are registered under the Exchange Act to file with the SEC initial reports of ownership and reports of changes of ownership of such registered securities.  To our knowledge, based solely on a review of such materials as are required by the SEC, none of our officers, directors or beneficial holders of more than 10% of our issued and outstanding shares of common stock failed to timely file with the SEC any form or report required to be so filed pursuant to Section 16(a) of the Exchange Act, during the fiscal year ended May 31, 2014.  Code of Ethics  In 2007, we adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions as well as to our directors and employees. A copy of our Code of Ethics will be provided to any person requesting same without charge. To request a copy of our Code of Ethics please make written request to our President c/o Rambo Medical Group, Inc. at 800 East Colorado Boulevard, Suite 888, Pasadena, CA 91101.       ITEM 11. EXECUTIVE COMPENSATION  The following table sets forth information concerning the total compensation paid or accrued by us during the two fiscal years ended May 31, 2014, and 2013 to (i) all individuals that served as our principal executive officer or acted in a similar capacity for us at any time during the fiscal year ended May 31, 2014; (ii) all individuals that were serving as executive officers of ours at the end of the fiscal year ended May 31, 2014 that received annual compensation during the fiscal year ended May 31, 2014 in excess of $100,000; and (iii) all individuals not serving as executive officers of ours at the end of the fiscal year ended May 31, 2014 that received annual compensation during the fiscal year ended May 31,2014 in excess of $100,000.  Summary Compensation Table  Name and Principal PositionYearSalary
($)Bonus
($)Stock Awards
($)Option Awards
($)Non-Equity Incentive Plan Compensation ($)Change in Pension Value and Non-qualified Deferred Compensation Earnings
($)All Other Compensation
($)Total
($)Dianwen Ju(1), President and Chief Executive Officer2014
20130
00
00
00
00
00
00
00
0Jimmy Wang, Treasurer2014
20130
00
00
00
00
00
00
00
0Xiao Chen(1), Chief Financial Officer2014
20130
00
00
00
00
00
00
00
0  We have not issued any stock options or maintained any stock option or other incentive plans since our inception. We have no plans in place and have never maintained any plans that provide for the payment of retirement benefits or benefits that will be paid primarily following retirement including, but not limited to, tax qualified deferred benefit plans, supplemental executive retirement plans, tax-qualified deferred contribution plans and nonqualified deferred contribution plans. Similarly, we have no contracts, agreements, plans or arrangements, whether written or unwritten, that provide for payments to the named executive officers or any other persons following, or in connection with the resignation, retirement or other termination of a named executive officer, or a change in control of us or a change in a named executive officers responsibilities following a change in control.  21    Employment Agreements  None of our current officers or directors have employment agreements with us.       ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS  The following table sets forth information with respect to the beneficial ownership of our common stock known by us as of September 15, 2014 by:  · each person or entity known by us to be the beneficial owner of more than 5% of our common stock; · each of our directors; · each of our executive officers; and · all of our directors and executive officers as a group.  The percentages in the table have been calculated on the basis of treating as outstanding for a particular person, all shares of our common stock outstanding on such date and all shares of our common stock issuable to such holder in the event of exercise of outstanding options, warrants, rights or conversion privileges owned by such person at said date which are exercisable within 60 days of September 15, 2014. Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent such power may be shared with a spouse.  Name of Beneficial OwnerTitle of ClassAmount and Nature
of Beneficial
Ownership(1)Percentage
of
Class(2)Chimerica Capital, LLC
800 East Colorado Blvd,
Suite 888
Pasadena, CA 91101Common Stock,
$0.00001 par value350,000 shares, direct(3)35.3%Baden Energy Group Ltd.
Rue Du Rhone 14
1204 Geneva, SwitzerlandCommon Stock,
$0.00001 par value65,256 shares, direct6.58%Dianwen Ju
800 East Colorado Blvd,
Suite 888
Pasadena, CA 91101Common Stock,
$0.00001 par value50,000 shares, direct5.04%Jimmy Wang
800 East Colorado Blvd,
Suite 888
Pasadena, CA 91101Common Stock,
$0.00001 par value400,000,000 shares: 50,000 direct and 350,000 indirect(3)40.36%Xiao Chen
800 East Colorado Blvd,
Suite 888
Pasadena, CA 91101Common Stock,
$0.00001 par value50,000 shares owned5.04%Goufeng Xu
800 East Colorado Blvd,
Suite 888
Pasadena, CA 91101Common Stock,
$0.00001 par valueAll directors and executive officers as a group (4 persons)Common Stock,
$0.00001 par value500,000 shares(3)50.45%   22    (1) As used herein, the term beneficial ownership with respect to a security is defined by Rule 13d-3 under the Securities Exchange Act of 1934 as consisting of sole or shared voting power (including the power to vote or direct the vote) and/or sole or shared investment power (including the power to dispose or direct the disposition of) with respect to the security through any contract, arrangement, understanding, relationship or otherwise, including a right to acquire such power(s) during the next 60 days. Unless otherwise noted, beneficial ownership consists of sole ownership, voting and investment rights. (2) There were 991,192 shares of common stock issued and outstanding on September 15, 2014. (3) Jimmy Wang has the power to vote and dispose of the shares owned by Chimerica Capital, LLC.  Changes in Control  Not Applicable.  Securities Authorized for Issuance Under Equity Compensation Plans  We do not presently maintain any equity compensation plans and have not maintained any such plans since our inception.       ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE  Director Independence  Our sole present director is not independent as that term is defined by the National Association of Securities Dealers Automated Quotations (NASDAQ) as our director also serves as one of our executive officers.          ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES  Audit Fees.  The aggregate fees billed to us by our principal accountant for services rendered during the fiscal years ended May 31, 2013 and 2012 are set forth in the table below:  Fee CategoryFiscal year ended May 31, 2014Fiscal year ended May 31, 2013Audit fees(1)$2,750$7,150Audit-related fees(2)$0$0Tax fees(3)$0$0All other fees(4)$0$0Total fees$2,750$7,150  (1) Audit fees consist of fees incurred for professional services rendered for the audit of consolidated financial statements, for reviews of our interim consolidated financial statements included in our quarterly reports on Form 10-Q and for services that are normally provided in connection with statutory or regulatory filings or engagements. (2) Audit-related fees consist of fees billed for professional services that are reasonably related to the performance of the audit or review of our consolidated financial statements, but are not reported under Audit fees. (3) Tax fees consist of fees billed for professional services relating to tax compliance, tax planning, and tax advice. (4) All other fees consist of fees billed for all other services.  Audit Committees Pre-Approval Practice.  Prior to our engagement of our independent auditor, such engagement was approved by our Board. The services provided under this engagement may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. Pursuant our requirements, the independent auditors and management are required to report to our board of directors at least quarterly regarding the extent of services provided by the independent auditors in accordance with this pre-approval, and the fees for the services performed to date. Our board of directors may also pre-approve particular services on a case-by-case basis. All audit-related fees, tax fees and other fees incurred by us for the years ended May 31, 2014 and 2013 were approved by our Board.        23    PART IV       ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES


|                                                                                                                                              |  |     
|--------------------------------------------------------------------------------------------------------------------------------------------- |  | ----
|Financial Statements                                                                                                                          |  | Page
|                                                                                                                                              |  |     
|Report of Independent Registered Public Accounting Firm                                                                                       |  | F-2 
|                                                                                                                                              |  |     
|Balance Sheets as of May 31, 2014 and 2013                                                                                                    |  | F-4 
|                                                                                                                                              |  |     
|Statements of Operations for the years ended May 31, 2014 and 2013 and for the period from November 18, 2005 (Inception) through May 31, 2014 |  | F-5 
|                                                                                                                                              |  |     
|Statements of Changes in Stockholders Equity (Deficit) for the period from November 18, 2005 (Inception) through May 31, 2014                |  | F-6 
|                                                                                                                                              |  |     
|Statements of Cash Flows for the years ended May 31, 2014 and 2013 and for the period from November 18, 2005 (Inception) through May 31, 2014 |  | F-7 
|                                                                                                                                              |  |     
|Notes to the Financial Statements                                                                                                             |  | F-8 

Financial Statement Schedules  All financial statement schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.  Exhibits  In reviewing the agreements included as exhibits to this Annual Report, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about our company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:  · should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; · have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; · may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and · were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.   24    Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Annual Report and our other public filings, which are available without charge through the SECs website at http://www.sec.gov.  The following exhibits are included as part of this report:


|            |  |                                                                                                                  
|----------- |  | -----------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                      
|            |  |                                                                                                                  
|3.1         |  | Articles of Incorporation of the Registrant, as filed with the Nevada Secretary of State on November 18, 2005 (1)
|            |  |                                                                                                                  
|3.2         |  | Certificate of Amendment filed with the Nevada Secretary of State on October 14, 2009 (2)                        
|            |  |                                                                                                                  
|3.3         |  | Certificate of Amendment filed with the Nevada Secretary of State on August 5, 2013 (16)                         
|            |  |                                                                                                                  
|3.4         |  | Bylaws of the Registrant (1)                                                                                     
|            |  |                                                                                                                  
|4.1         |  | Warrant dated August 12, 2009 exercisable for 319,419 shares issued to Baden Energy Group Ltd. (3)               
|            |  |                                                                                                                  
|4.2         |  | Warrant dated September 22, 2009 excercisable for 60,000 shares issued to Baden Energy Group Ltd. (4)            
|            |  |                                                                                                                  
|10.1        |  | Assignment of Quit Claim of Oil and Gas Leases, dated May 15, 2006 (1)                                           
|            |  |                                                                                                                  
|10.2        |  | Joint Venture Agreement with DNR Oil & Gas Inc., dated May 15, 2006 (1)                                          
|            |  |                                                                                                                  
|10.3        |  | Joint Venture Agreement with Colorado Oil & Gas, Inc., dated May 15, 2006 (1)                                    
|            |  |                                                                                                                  
|10.4        |  | Well Service and Operating Agreement dated May 11, 2007 between Registrant and DNR Oil & Gas Company (5)         
|            |  |                                                                                                                  
|10.5        |  | Memorandum of Intent, dated May 22, 2008 between Registrant and Coastal Petroleum Company (6)                    
|            |  |                                                                                                                  
|10.6        |  | Executive Employment Agreement effective June 5, 2008 between Registrant and Massimiliano Pozzoni (7)            
|            |  |                                                                                                                  
|10.7        |  | Assignment of Farmout Interest dated June 16, 2008 between Registrant and West Canyon Energy Corp. (8)           
|            |  |                                                                                                                  
|10.8        |  | Formal Agreement dated June 18, 2008 between Registrant and Coastal Petroleum Corp. (8)                          
|            |  |                                                                                                                  
|10.9        |  | Share Issuance Agreement dated July 6, 2009 between Registrant and Baden Energy Group Ltd. (10)                  
|            |  |                                                                                                                  
|10.10       |  | Purchase Agreement dated July 25, 2009 between Registrant and Enercor, Inc. (11)                                 
|            |  |                                                                                                                  
|10.11       |  | Purchase Agreement dated August 5, 2009 between Registrant and Enercor, Inc. (12)                                
|            |  |                                                                                                                  
|10.12       |  | Purchase Agreement dated August 12, 2009 between Registrant and Enercor, Inc. (13)                               
|            |  |                                                                                                                  
|10.13       |  | July 6, 2009 Advisory Board Agreement with Warren Dillard (14)                                                   
|            |  |                                                                                                                  
|10.14       |  | Investment Agreement between Registrant and Dutchess Opportunity Fund II, LP, dated January 28, 2010 (2)         
|            |  |                                                                                                                  
|10.15       |  | Registration Rights Agreement between Registrant and Dutchess Opportunity Fund II, LP, dated January 28, 2010 (2)
|            |  |                                                                                                                  
|10.16       |  | Settlement Agreement, effective September 8, 2009 between Registrant and Cobra Oil & Gas Corporation (15)        
|            |  |                                                                                                                  
|14.1        |  | Code of Ethics (9)                                                                                               
|            |  |                                                                                                                  

25


|            |  |                                                                                                                                                 
|----------- |  | ------------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                                     
|16.1        |  | Letter from Sam Kan & Company regarding changes in Registrants certifying accountant (17)                                                      
|            |  |                                                                                                                                                 
|16.2        |  | Letter from KLJ & Associates, LLP regarding changes in Registrants certifying accountant (18)                                                  
|            |  |                                                                                                                                                 
|21*         |  | Subsidiaries of Registrant                                                                                                                      
|            |  |                                                                                                                                                 
|31.1*       |  | Certification of Principal Executive Officer pursuant to Rule 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended  
|            |  |                                                                                                                                                 
|31.2*       |  | Certification of Principal Financial Officer pursuant to Rule 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended  
|            |  |                                                                                                                                                 
|32.1**      |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)
|            |  |                                                                                                                                                 
|32.2**      |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)
|            |  |                                                                                                                                                 
|101.INS    |  | XBRL Instance Document                                                                                                                          
|            |  |                                                                                                                                                 
|101.SCH    |  | XBRL Schema Document                                                                                                                            
|            |  |                                                                                                                                                 
|101.CAL    |  | XBRL Calculation Linkbase Document                                                                                                              
|            |  |                                                                                                                                                 
|101.DEF    |  | XBRL Definition Linkbase Document                                                                                                               
|            |  |                                                                                                                                                 
|101.LAB    |  | XBRL Label Linkbase Document                                                                                                                    
|            |  |                                                                                                                                                 
|101.PRE    |  | XBRL Presentation Linkbase Document                                                                                                             

* Filed herewith.  ** This certification is being furnished and shall not be deemed filed with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.   Pursuant to Rule 406T of Regulation S-T, this XBRL related information shall not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed part of a registration statement, prospectus or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filings.  (1) Filed as an exhibit, numbered as indicated above, to Registrants Registration Statement on Form SB-2, as filed with the Securities and Exchange Commission on July 25, 2006, which exhibit is incorporated herein by reference. (2) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K, dated October 14, 2009, as filed with the Securities and Exchange Commission on February 3, 2010, which exhibit is incorporated herein by reference. (3) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated August 12, 2009, as filed with the Securities and Exchange Commission on August 17, 2009, which exhibit is incorporated herein by reference. (4) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated September 22, 2009, as filed with the Securities and Exchange Commission on September 25, 2009, which exhibit is incorporated herein by reference. (5) Filed as an exhibit, numbered as indicated above, to Registrants Quarterly Report on Form 10-QSB for the quarter ended August 31, 2007, as filed with the Securities and Exchange Commission on October 15, 2007, which exhibit is incorporated herein by reference.  26    (6) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated May 22, 2008, as filed with the Securities and Exchange Commission on May 27, 2008, which exhibit is incorporated herein by reference. (7) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated June 5, 2008, as filed with the Securities and Exchange Commission on June 6, 2008, which exhibit is incorporated herein by reference. (8) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated June 10, 2008, as filed with the Securities and Exchange Commission on July 2, 2008, which exhibit is incorporated herein by reference. (9) Filed as an exhibit, numbered as indicated above, to Registrants Annual Report on Form 10-KSB for the year ended May 31, 2007, as filed with the Securities and Exchange Commission on August 28, 2007, which exhibit is incorporated herein by reference. (10) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated July 6, 2009, as filed with the Securities and Exchange Commission on July 14, 2009, which exhibit is incorporated herein by reference. (11) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated July 25, 2009, as filed with the Securities and Exchange Commission on July 30, 2009, which exhibit is incorporated herein by reference. (12) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated August 5, 2009, as filed with the Securities and Exchange Commission on August 11, 2009, which exhibit is incorporated herein by reference. (13) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated August 12, 2009, as filed with the Securities and Exchange Commission on August 17, 2009, which exhibit is incorporated herein by reference. (14) Filed as an exhibit, numbered as indicated above, to Registrants Annual Report on Form 10-K for the year ended May 31, 2009, as filed with the Securities and Exchange Commission on August 20, 2009, which exhibit is incorporated herein by reference. (15) Filed as an exhibit, numbered as indicated above, to Registrants Quarterly Report on Form 10-Q for the quarter ended August 31, 2009, which exhibit is incorporated herein by reference. (16) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated August 5, 2013, as filed with the Securities and Exchange Commission on August 8, 2013, which exhibit is incorporated herein by reference. (17) Filed as an exhibit, numbered as indicated above, to Registrants Current Report on Form 8-K dated August 13, 2013, as filed with the Securities and Exchange Commission on August 15, 2013, which exhibit is incorporated herein by reference. (18) Filed as an exhibit, numbered Exhibit 16.1, to Registrants Current Report on Form 8-K dated February 13, 2014, as filed with the Securities and Exchange Commission on February 19, 2014, which exhibit is incorporated herein by reference.  27   SIGNATURES  Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   RAMBO MEDICAL GROUP, INC.   Dated: September 15, 2014 By: /s/ Dianwen Ju Name: Dianwen Ju Title: President and Chief Executive Officer   Dated: September 15, 2014 By: /s/ Xiao Chen Name: Xiao Chen Title: Chief Financial and Accounting Officer   Pursuant to the requirements of the Exchange Act this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on this 15th day of September, 2014.   /s/ Dianwen Ju Dianwen Ju, President, Chief Executive Officer, and Director     28   FINANCIAL STATEMENTS  INDEX TO FINANCIAL STATEMENTS


|                                                                                                                                                                           |  |     
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ----
|                                                                                                                                                                           |  | Page
|                                                                                                                                                                           |  |     
|Reports of Independent Registered Public Accounting Firms                                                                                                                  |  | F-2 
|                                                                                                                                                                           |  |     
|Balance Sheets as of May 31, 2014 and 2013 (audited)                                                                                                                       |  | F-4 
|                                                                                                                                                                           |  |     
|Statements of Operations for the years Ended May 31, 2014 and 2013 (audited) and for the period from November 18, 2005 (dated of inception) through May 31, 2014 (audited) |  | F-5 
|                                                                                                                                                                           |  |     
|Statements of Stockholders Equity for the period from November 18, 2005 (dated of inception) through May 31, 2014 (audited)                                               |  | F-6 
|                                                                                                                                                                           |  |     
|Statements of Cash Flows for the years Ended May 31, 2014 and 2013 (audited) and for the period from November 18, 2005 (dated of inception) through May 31, 2014 (audited) |  | F-7 
|                                                                                                                                                                           |  |     
|Notes to the Financial Statements (audited)                                                                                                                                |  | F-8 

F-1   [f10k053114_10k001.jpg]  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   The Board of Directors and Stockholders of Rambo Medical Group, Inc.   We have audited the accompanying balance sheet of Rambo Medical Group, Inc. (the Company) as of May 31, 2014, and the related statements of operations, changes in stockholders deficit and cash flows for the year then ended May 31, 2014. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. The financial statements of the Company as of May 31, 2013, were audited by other auditors, whose report, dated August 26, 2013, expressed an unqualified opinion on those financial statements.  We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States of America). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that we considered appropriate under the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Companys internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.  In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Rambo Medical Group, Inc. as of May 31, 2014, and the results of their operations and their cash flows for the year ended May 31, 2014, in conformity with accounting principles generally accepted in the United States of America.  The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has experienced recurring operating losses and negative cash flow since inception and has financed its working capital requirements through issuance of notes payable, common stock, and advances from related parties. These conditions, among others, raise substantial doubt about the Companys ability to continue as a going concern. Management's plans concerning these matters are also described in Note 3 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   /s/ Anton & Chia, LLP   Newport Beach, California September 15, 2014  F-2   [f10k053114_10k002.jpg]  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  To the Board of Directors and Stockholders Rambo Medical Group, Inc. (f/k/a Viper Resources, Inc.)  We have audited the accompanying balance sheet of Rambo Medical Group, Inc. (f/k/a Viper Resources, Inc.) (a development stage company) (the Company) as of May 31, 2013 and the related statements of operations, stockholders equity, and cash flows for the year then ended. Rambo Medical Group, Inc.s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits  We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the companys internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.  In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Rambo Medical Group, Inc. as of May 31, 2013, and the results of its operations and its cash flows for year ended in conformity with accounting principles generally accepted in the United States of America.  The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company is in the development stage, has not earned significant revenue, has suffered net losses and has had negative cash flows from operating activities during the years ended May 31, 2013. These matters raise substantial doubt about the Companys ability to continue as a going concern. Managements plans concerning these matters are also described in Note 3. The financial statements do not include any adjustments to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.   /s/ KLJ & Associates, LLP  KLJ & Associates, LLP  St. Louis Park, MN August 26, 2013     1660 Highway 100 South Suite 500 St. Louis Park, MN 55416 630.277.2330   F-3    Rambo Medical Group, Inc.BALANCE SHEETSMay 31,May 31,20142013ASSETSCurrent assetsCash$6,707$4,458Total assets (all current)$6,707$4,458LIABILITIES AND STOCKHOLDERS' DEFICITCurrent liabilitiesAccounts payable$791$10,791Due to related party$88,859$55,000Total current liabilities89,65065,791Non-Current liabilitiesDue to related party, net of current portion20,000-Total liabilities109,65065,791Stockholders' deficitPreferred stock, $.00001 par value; 100,000,000 shares authorized; no shares issued or outstanding--Common stock, $.00001 par value; 300,000,000 authorized; 992,192 shares issued and outstanding as of May 31, 2014 and May 31, 2013991991Additional paid in capital7,043,2227,043,222Accumulated deficit(7,147,156)(7,105,546)Total stockholders' deficit(102,943)(61,333)Total liabilities and stockholders' deficit$6,707$4,458The accompanying notes are an integral part of these financial statements.    F-4    Rambo Medical Group, Inc.STATEMENTS OF OPERATIONSFor the year endedFor the year endedMay 31,May 31,20142013Revenue$-$-Operating expensesGeneral and administrative expenses41,61038,090Total operating expenses41,61038,090Loss from operations(41,610)(38,090)Net loss$(41,610)$(38,090)Basic and diluted loss per common shares$(0.04)$(0.04)Weighted average shares outstanding992,192992,192The accompanying notes are an integral part of these financial statements.   F-5    Rambo Medical Group, Inc.STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICITPreferred StockCommon StockAdditional Paid-inDeficitStockholders'SharesAmount
($)SharesAmount
($)Capital
($)Accumulated ($)Equity
($)Balance at May 31, 2012--992,1929917,043,222(7,067,456)(23,243)Net loss for the period ended-----(38,090)(38,090)Balance at May 31, 2013--992,1929917,043,222(7,105,546)(61,333)Net loss for the period ended-----(41,610)(41,610)Balance at May 31, 2014--992,1929917,043,222(7,147,156)(102,943)  The accompanying notes are an integral part of these financial statements.  F-6    Rambo Medical Group, Inc.STATEMENTS OF CASH FLOWSFor the year endedFor the year endedMay 31,May 31,20142013Operating Activities:Net loss$(41,610)$(38,090)Changes operating assets and liabilities:Accounts payable(10,000)5,309Due to related party53,85925,000Net cash provided by (used in) operating activities2,249(7,781)Net increase (decrease) in cash2,249(7,781)Cash at the beginning of period4,45712,238Cash at the end of period$6,707$4,457Supplemental disclosures of cash flow Information:Cash paid for interest$-$-Cash paid for income taxes$-$-The accompanying notes are an integral part of these financial statements.   F-7   RAMBO MEDICAL GROUP, INC. (A Development Stage Company)  NOTES TO THE FINANCIAL STATEMENTS May 31, 2014 and 2013  NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS  Rambo Medical Group, Inc., formerly known as Viper Resources, Inc., was incorporated in the State of Nevada on November 18, 2005. On October 14, 2009, the Company filed a Certificate of Amendment to its Articles of Incorporation to increase its shares of authorized common stock from 100,000,000 to 300,000,000 and to change its name from Cobra Oil and Gas Company to Viper Resources, Inc. The Company was originally formed to engage in identifying, investigating, exploring, and where determined advantageous, developing, mining, refining, and marketing oil and gas. The Company may also engage in any other business permitted by law, as designated by the Board of Directors of the Company. On April 25, 2011, the Companys previous management was replaced in its entirety. The Companys new management term is currently evaluating the Companys business operations and plans to make a determination on whether the Company will continue operating in the oil and gas industry.  NOTE 2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  A summary of significant accounting policies of Rambo Medical Group, Inc. (hereinafter the "Company"), a company organized in the state of Nevada (A Development Stage Company) is presented to assist in understanding the Company's financial statements. The accounting policies presented in these footnotes conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the accompanying financial statements. These financial statements and notes are representations of the Company's management who are responsible for their integrity and objectivity. The Company has not realized significant revenues from its planned principal business purpose and is considered to be in its development state in accordance with ASC 915, "Development Stage Entities", formerly known as SFAS 7, Accounting and Reporting by Development State Enterprises.  Basis of Presentation  Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of our financial statements requires us to make estimates and assumptions that affect, among other areas, the reported amounts of trade receivable reserves and inventory reserves, impairment of long-lived assets, and recoverability of deferred tax assets. These estimates and assumptions also impact revenues, expenses and the disclosures in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.  Development Stage  The Company is currently in the development stage and has no significant operations. On August 8, 2013, the Company is approved to change name to Rambo Medical Group, Inc. and a 1-for-100 reverse split of the outstanding common stocks. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented.  Fair Value Measurements  In January 2010, the FASB ASC Topic 825, Financial Instruments, began requiringdisclosures about fair value of financial instruments in quarterly reports as well as in annual reports. For the Company, this statement applies to certain investments and long-term debt. Also, FASB ASC Topic 820, Fair Value Measurements and Disclosures, clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.  F-8    Various inputs are considered when determining the value of the Companys investments and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.  · Level 1  observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets. · Level 2  other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.). · Level 3  significant unobservable inputs (including the Companys own assumptions in determining the fair value of investments).  The Companys adoption of FASB ASC Topic 825 effectively at the inception did not have a material impact on the Companys financial statements.  The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company does not have financial assets as an investment carried at fair value on a recurring basis as of May 31, 2014 and 2013.  The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment. As of May 31, 2014 and 2013, the Company had assets and liabilities in cash, property and equipments that were fully depreciated, and various payables. Management believes that they are being presented at their fair market value.  Use of Estimates  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company is subject to uncertainty of future events, economic, environmental and political factors and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, accounting estimates used in the preparation of the Company's financial statements will change as new events occur and that more experience is acquired, as additional information is obtained and as the Company's operating environment changes. Changes are made in estimates as circumstances warrant. Such changes in estimates and refinement of estimation methodologies are reflected in the statements.  Cash and Cash Equivalents  Cash and cash equivalents include short-term, highly liquid investments with maturities of less than three months when acquired. The Company had $6,707 and $4,458 in cash on May 31, 2014 and 2013, respectively. The Company had no cash equivalent on May 31, 2014 and 2013.  Accounts Payable  Services and goods received from vendors and billed but not yet paid are recorded as accounts payable in periods when the services and goods were received. As of May 31, 2014, $791 was recorded as accounts payable to related party. As of May 31, 2013, $10,791 was recorded as accounts payable.  F-9    Income Tax  The Company accounts for income taxes under Accounting Standards Codified No. 740 (ASC 740). Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.  Stock Based Compensation  The Company accounts for employee and non-employee stock awards under ASC 718, whereby equity instruments issued to employees for services are recorded based on the fair value of the instrument issued and those issued to non-employees are recorded based on the fair value of the consideration received or the fair value of the equity instrument, whichever is more reliably measurable.  Net Income (Loss) per Share  The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Companys preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share.  Basic Loss per Share  The Company computes net loss per share in accordance with ASC 260,Accounting for Earnings per Share. Under the provisions of ASC 260, basic net loss per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. The calculation of diluted net loss per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.  Basic net loss per common share is based on the weighted average number of shares of common stock outstanding since inception. As of May 31, 2014 and 2013, the Company had 992,192 and 992,192 common shares outstanding, respectively.  The computations of basic loss per share of common stock are based on the weighted average number of share outstanding at the date of the financial statements. As of May 31, 2013, there were no common stock equivalents outstanding.  Loss
(Numerator)W.A. Shares (Denominator)Loss per Share (Amount)For the year ended May 31, 2013$(38,090)992,192$(0.04)For the year ended May 31, 2014$(41,610)992,192$(0.04)  Recently Issued Accounting Pronouncements  In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and shareholders equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The Companys early adoption of the new standard is not expected to have a material effect on the Companys consolidated financial position or results of operations.  F-10    NOTE 3. GOING CONCERN  Under the going concern assumption, an entity is ordinarily viewed as continuing in business for the foreseeable future with neither the intention nor the necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to laws or regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business.  The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations from the development of its planned business. Management has plans to seek additional capital through a public or private offering of equity or debt securities, or by other means. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.  There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from the operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might necessary in the event the Company cannot continue in existence.  NOTE 4. RELATED PARTY TRANSACTIONS  On November 4, 2013, the company took a loan from American Compass Inc. (ACI), in the amount of $10,000. This is a no interest bearing and unsecured loan due on November 4, 2015. On April 17, 2014, the Company accepted another loan from ACI in the amount of $10,000. This is a non-interest bearing and unsecured loan due on April 17, 2016. As of May 31, 2014, the total balance of loan from ACI is $108,859.  Year ended May 31,Current$88,859201520,0002016-2017-$108,859  NOTE 5. COMMON STOCK  The Company is authorized to issue 100,000,000 shares of preferred stock with par values in $.00001. The Company is also authorized to issue 300,000,000 shares of common stock with par values in $.00001. On May 6, 2008, the Company effected a forward split of 35 for each share of common stock. On July 20, 2010, the Company issued 50,000 shares of common stock to investors at a price of $2 per unit for a total of $100,000. The Company had issued a total of 0.15 million shares of common stock to compensate its officers during the fiscal year of 2012. In order to seek alternative business development and future merging and stock offering, the shareholders of Viper Resource Inc. approved to a 1:100 reverse stock split and change the name to Rambo Medical Group Inc. on August 8, 2013. There were 992,192 and 992,192 shares issued and outstanding as of May 31, 2014 and May 31, 2013 respectively.  NOTE 6. OFFICE LEASE  Since May 2011, the company has not had a formal office lease. The Company uses office space provided by one of its officers on a rent free basis.  F-11    NOTE 7. WARRANTS  At May 31, 2008, the Company had 10,000 common stock purchase warrants outstanding, originally sold as part of a unit, allowing the holder to purchase one share of common stock at an exercise price of $40, anytime through May 15, 2011. In fiscal year 2009, the Company sold 10,000 units to an investor for cash at $25 per unit, or an aggregate of $250,000. Each unit consists of one share of common stock, and one warrant to purchase one share of common stock at an exercise price of $40, anytime through June 9, 2011. At May 31, 2009, none of the warrants had been exercised, leaving a year end balance of 20,000 warrants. The entire value of the units of $250,000 was assigned to the common stock as the warrants are non-detachable.  In fiscal year 2010, the Company sold 20,252 units to investors for cash at prices ranging from $17 - $100 per unit, or an aggregate of $1,250,000. Each unit consists of one share of common stock, and one warrant to purchase one share of common stock at exercise prices ranging from of $20 - $125, anytime through expiration dates from June 2012 through February 2013. The entire value of the units was assigned to the common stock as the warrants are non-detachable. At May 31, 2010, none of the warrants had been exercised or had expired, leaving a year end balance of 40,252 warrants.  During the year ended May 31, 2011, the Company sold 50,000 units to investors at a price of $2 per unit for a total of $100,000. Each unit consists of one share of common stock, and one warrant to purchase one share of common stock at an exercise price of $2.5, anytime through expiration date of July 2013. The entire value of the units was assigned to the common stock as the warrants are non-detachable. As of May 31, 2011, none of the warrants have been exercised. During the fiscal year of 2011, 10,000 warrants expired, leaving a year-end balance of 80,252 warrants.  During the year ended May 31, 2012, 10,000 warrants expired, leaving a year-end balance of 70,252 warrants.  During the year ended May 31. 2013, 20,252 warrants expired, leaving a year-end balance of 50,000 warrants.  During the year ended May 31. 2014, 50,000 warrants expired, leaving no warrants currently outstanding.  NOTE 8. INCOME TAX  The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.  Net deferred tax assets consist of the following components as of May 31, 2014 and 2013:  20142013Deferred tax assets:NOL carryover$7,147,156$7,105,546Valuation allowance7,147,156(7,105,546)Net deferred tax asset$-$-   F-12    The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates of 39% to pretax income from continuing operations for the period ended May 31, 2014 due to the following:  20142013Income tax benefit at statutory rate$(2,787,391)$(2,771,162)Valuation allowance2,787,3912,771,162$-$-  At May 31, 2014 and 2013, the Company had net operating loss carryforwards of approximately $7,147,156 and $7,105,546 which begin to expire in 2026. Deferred tax assets of approximately $2,787,391 and $2,771,162 in 2013 and 2012 created by the net operating losses have been offset by a 100% valuation allowance.  NOTE 9. COMMITMENTS AND CONTINGENCIES  The Company could become a party to various legal actions arising in the ordinary course of business. Matters that are probable of unfavorable outcomes to the Company and which can be reasonably estimated are accrued. Such accruals are based on information known about the matters, the Companys estimates of the outcomes of such matters and its experience in contesting, litigating and settling similar matters.  As of the date of this annual report, there are no material pending legal proceedings to which the Company is a party or of which any of their property is the subject, nor are there any such proceedings known to be contemplated by governmental authorities.[f10k053114_10k004.gif]  F-13